Dr. Denduluri On Treatment For Er+/Her2- Breast Cancer

Dr. Denduluri on Treatment for ER+/HER2- Breast Cancer

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

Dr. Denduluri on the Role of Neoadjuvant Therapy in HER2+ Breast Cancer

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

Dr. Denduluri on the Use of the Oncotype DX Assay in Early-Stage HR+/HER2- Breast Cancer

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

Get ALL the info you need about HER2 +ve BREAST CANCER - HER2 +ve BREAST CANCER || Dr Liz O'Riordan

Dr Liz O'Riordan

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

ER positive, PR positive, HER2 negative in Breast Cancer Treatment - Dr. Nanda Rajaneesh

Doctors' Circle World's Largest Health Platform

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

Her-2 Positive Breast Cancer

SERDs for patients with ER+/HER2- breast cancer

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. Gradishar

Total Health | Oncology

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and More

PeerView Oncology

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. Soliman

Total Health | Oncology

Treatment Options for ER/PR Positive or Negative Breast Cancer

Yerbba – Breast Cancer

Treatment for Early-Stage ER+ Breast Cancer